Your browser doesn't support javascript.
loading
Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
Shafiee, Soodabeh; Mirzaei, Roya; Salehi, Malihe; Jalili, Neda; Taheri, Amir; Farahmand, Leila.
Afiliación
  • Shafiee S; Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Mirzaei R; Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Salehi M; Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Jalili N; Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Taheri A; Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Farahmand L; Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Iran J Immunol ; 20(3): 303-315, 2023 09 01.
Article en En | MEDLINE | ID: mdl-37434357
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Iran J Immunol Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Antineoplásicos Límite: Female / Humans Idioma: En Revista: Iran J Immunol Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán